Ranking Profile - Catalent Inc


Catalent Inc (Catalent) provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The company offers complex advanced formulation delivery technologies, and related integrated solutions. It provides comprehensive pre-formulation, development, and both clinical and commercial scale for most traditional and advanced oral solid dose formats. Catalent also offers a wide range of injectable manufacturing solutions including filling drugs or biologics into pre-filled syringes and glass-free vials as well as formulation development and cell-line manufacturing. The company has manufacturing facilities in North America and Europe. Catalent is headquartered in Somerset, New Jersey, the US.

Company info

Country (HQ): United States
Sector: Pharmaceuticals and Healthcare
Market Cap (US$ m): 5,785
Revenue (US$ m): 4,828 (2022)

Innovation ranking


Innovation score

Closest peers in the Pharmaceuticals and Healthcare sector

Innovation Ranking


Johnson & Johnson

United States

Pharmaceuticals and Healthcare

F. Hoffmann-La Roche Ltd


Pharmaceuticals and Healthcare

Catalent Inc

United States

Pharmaceuticals and Healthcare

EyeGate Pharmaceuticals Inc

United States

Pharmaceuticals and Healthcare

Shin Poong Pharm Co Ltd

South Korea

Pharmaceuticals and Healthcare

Are you ranked? Get the Innovation Ranking Report

  • Company Ranking Report
    • If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
    • Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
    • Contextualised information on the company's standing in relation to peers
    • Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
    • Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
  • Rosettes
  • Certificate of Achievement
  • Press release
Screenshot of Deal Makers